Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 19/20 | 0.72 |
| ▸ | HTR3A | P46098 | 6/20 | 0.72 |
| ▸ | HTR3B | O95264 | 1/20 | 0.72 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772481 | 1.00 | HRH4 (0.72) | HRH4HTR3AHTR3BHRH3 | |
| SCHEMBL27661218 | 0.87 | HRH4 (0.70) | HRH4HTR3AHTR3BHRH3 | |
| SCHEMBL404202 | 0.87 | HRH4 (0.70) | HRH4HTR3AHTR3BHRH3 | |
| SCHEMBL6362360 | 0.85 | HRH4 (0.68) | HRH4HTR3AHTR3BHRH3 | |
| SCHEMBL404203 | 0.84 | HRH4 (1.00) | HRH4HTR3AHTR3B | |
| SCHEMBL30223251 | 0.84 | HRH4 (0.73) | HRH4HTR3AHTR3B | |
| SCHEMBL405806 | 0.84 | HRH4 (0.73) | HRH4HTR3AHTR3B | |
| SCHEMBL606760 | 0.83 | HRH4 (1.00) | HRH4HTR3AHTR3BHRH3 | |
| Hydrochloric Acid SCHEMBL29694104 | 0.83 | HRH4 (0.97) | HRH4HTR3AHTR3B | |
| SCHEMBL440993 | 0.82 | HRH4 (0.63) | HRH4HTR3AHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670774-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005033088-A1 | QUINOXALINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-14 | — | — | WO | disclosed |
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070527-A1 | For leukocyte recruitment inhibition, treating or preventing inflammation and H4 receptor-mediated conditions | HRH4, HRH3, LTB4R | HRH4 1/4885HTR3A 225/4885HTR3B 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.